Enovis Corporation (ENOV) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended April 3, 2026. Enovis Corporation is an innovation-driven medical technology company operating through two segments: Prevention & Recovery (P&R), focusing on orthopedic and recovery science solutions, and Reconstructive (Recon), providing surgical implant solutions. The company is a large accelerated filer with 57.6 million shares of common stock outstanding as of May 1, 2026.
Key Financial Metrics
| Metric (in millions) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $589.2 | $558.8 |
| Gross Profit | $365.5 | $332.2 |
| Gross Margin | 62.0% | 59.4% |
| Operating Income | $6.5 | $(46.8) |
| Net Loss (GAAP) | $(8.5) | $(55.7) |
| Adjusted EBITDA (Non-GAAP) | $103.6 | $87.1 |
| Adjusted EBITDA Margin | 17.6% | 15.6% |
| Cash from Operations | $24.0 | $(1.6) |
| Total Debt | $1,326.0 | $1,296.8 |
| Cash & Equivalents | $33.1 | $38.5 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5.4% year-over-year, driven by a 3.3% increase in existing business sales and a 4.2% favorable impact from foreign currency translation. This was partially offset by a 2.3% decrease due to the October 2025 divestiture of the Dr. Comfort Footcare Solutions product line.
- Profitability Improvement: The company returned to operating profitability ($6.5M) from a significant loss ($46.8M) in the prior year. This turnaround was primarily due to the absence of a $35.8M "Purchase of royalty interest" charge recorded in Q1 2025 and a $12.1M reduction in inventory fair value step-up amortization charges.
- Segment Performance:
- Reconstructive: Sales grew 10.8% to $317.1M, with Adjusted EBITDA rising to $72.5M (22.9% margin). Growth was driven by volume and favorable FX.
- Prevention & Recovery: Sales remained flat at $272.0M, with Adjusted EBITDA slightly increasing to $31.1M (11.4% margin).
- Cash Flow: Operating cash flow improved significantly to $24.0M from a use of $1.6M in the prior year, aided by improved gross profit and working capital management.
Guidance, Outlook, and Risks
- Management Commentary: Management highlighted strong volume growth in the Recon segment and improved product mix. They noted that strategic transaction costs (primarily related to the Lima Acquisition integration) were $11.0M in Q1 2026, down from $12.1M in the prior year.
- Capital Structure: The company maintains a $1.1 billion revolving credit facility with $906 million available as of April 3, 2026. A $700 million term loan matures in 2030. The company remains in compliance with all debt covenants.
- Key Risks:
- Foreign Exchange: Approximately 46% of sales are outside the U.S., exposing the company to currency fluctuations.
- Regulatory: Ongoing costs related to EU Medical Device Regulation (MDR) compliance ($0.8M in Q1 2026).
- Integration: Risks associated with successfully integrating recent acquisitions, particularly the Lima Acquisition.
- Macroeconomic: Potential impacts from tariffs, inflation, and geopolitical tensions.
- Unusual Items: The company revised its definition of Adjusted EBITDA to no longer adjust for inventory step-up charges, resulting in a restatement of prior period non-GAAP figures.
Investor Verification Checklist
- Non-GAAP Adjustments: Verify the impact of the revised Adjusted EBITDA definition (removal of inventory step-up adjustments) on historical comparability.
- Debt Covenants: Confirm continued compliance with the 3.50:1.00 senior secured leverage ratio and 3.00:1.00 interest coverage ratio given the current debt load.
- FX Sensitivity: Assess the sustainability of the 4.2% revenue boost from foreign currency translation given global economic volatility.
- Integration Costs: Monitor the trajectory of strategic transaction costs related to the Lima Acquisition to ensure they decline as integration completes.
- Divestiture Impact: Evaluate the long-term revenue impact of the Dr. Comfort divestiture on the P&R segment's growth trajectory.